Epigral Share Price

NSE
EPIGRAL •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Epigral
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
27.78% Fall from 52W High
-9.9
TTM PE Ratio
Below industry Median
21.5
Price to Book Ratio
Below industry Median
5.3
Dividend yield 1yr %
Below industry Median
0.4
TTM PEG Ratio
PEG TTM is less than 1
0.3

Epigral Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Epigral Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
645.24 Cr
626.06 Cr
651.2 Cr
524.63 Cr
471.52 Cr

Epigral Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021
1935.76 Cr
2196.38 Cr
1555.05 Cr
830.79 Cr

Epigral Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
103.54 Cr
80.53 Cr
86.01 Cr
76.67 Cr
49.31 Cr

Epigral Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021
195.84 Cr
353.31 Cr
252.79 Cr
100.84 Cr
Epigral Result Highlights
  • Epigral Ltd reported a 2.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 36.9%.

  • Its expenses for the quarter were down by 2.3% QoQ and up 23.9% YoY.

  • The net profit increased 27.5% QoQ and increased 111.1% YoY.

  • The earnings per share (EPS) of Epigral Ltd stood at 24.3 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Epigral shareholding Pattern

Promoter
68.9%
Foreign Institutions
3%
Mutual Funds
4.2%
Domestic Institutions
4.3%
Public
23.7%
Promoter
71.6%
Foreign Institutions
2.1%
Mutual Funds
1%
Domestic Institutions
1.2%
Public
25.1%
Promoter
71.6%
Foreign Institutions
1.5%
Domestic Institutions
0.2%
Public
26.8%
Promoter
71.5%
Foreign Institutions
1.4%
Public
27.1%
Promoter
71.4%
Foreign Institutions
1.2%
Public
27.4%
Promoter
71.4%
Foreign Institutions
1.1%
Domestic Institutions
0.1%
Public
27.4%

Epigral Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
5Day EMA
1,767.80
10Day EMA
1,789.40
12Day EMA
1,794.60
20Day EMA
1,805.60
26Day EMA
1,812.10
50Day EMA
1,845.20
100Day EMA
1,866.80
200Day EMA
1,765.00
5Day SMA
1,763.20
10Day SMA
1,790.90
20Day SMA
1,830.10
30Day SMA
1,795.60
50Day SMA
1,824.80
100Day SMA
1,960.20
150Day SMA
1,950.10
200Day SMA
1,800.20
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
16226 Rs
34976 Rs
Week Rs
15773 Rs
45534 Rs
Month Rs
25552 Rs
87062 Rs
Resistance & Support
1,765.87
Pivot
Resistance
First Resistance
1,799.73
Second Resistance
1,861.37
Third Resistance
1,895.23
Support
First Support
1,704.23
Second support
1,670.37
Third Support
1,608.73
Relative Strength Index
44.98
Money Flow Index
36.28
MACD
-17.49
MACD Signal
-6.80
Average True Range
103.38
Average Directional Index
16.99
Rate of Change (21)
2.75
Rate of Change (125)
-12.08

Epigral Company background

Founded in: 2007
Managing director: Maulik Jayantibhai Patel
Epigral Limited was erstwhile incorporated as Meghmani Finechem Limited in 2007, which engaged in manufacturing and selling of Chlor Alkali its Derivatives and also in Trading of Agrochemical products. The Company was incorporated as a subsidiary of Meghmani Organics Limited. Meghmani Finechem Limited (MFL) was demerged from Meghmani Organics Limited (MOL) as a going concern through the Scheme of Arrangement for Demerger and the said Scheme became effective from May 10, 2021. The ChlorAlkali business commissioned in 2009, growing from an installed capacity of 1,88,000 TPA in 2015 to 3,15,000 TPA at the close of FY 202021. The Company is now among the leading players in Indias chlor alkali industry. In terms of the said Scheme, the Company allotted 2,39,03,029 Equity Shares of Rs 10/ each on 20th May, 2021 to the shareholders of Meghmani Organics Limited.The Company grew its business following the commissioning of new plants (Caustic Soda, Hydrogen Peroxide and the 36 MW Captive Power Plant). The timely commissioning of the plants represented the faith of the management in the longterm potential of the sector and country. The Caustic Soda capacity was expanded by 1,27,000 TPA to 2,94,000 TPA and commissioned in June 2020. The Captive Power Plant capacity was increased by 36 MW to 96 MW, commissioned in June 2020. The Company commissioned a 60,000 TPA Hydrogen Peroxide plant in July 2020. The Company further commissioned the capacity expansion of Caustic Soda manufacturing facility to 400 KTPA by adding 106 KTPA facility, along with expansion of 36 MW Captive Power Plant on 30th September, 2022. It commissioned Epichlorohydrin (ECH) manufacturing facility with a capacity of 50,000 TPA on 1st June, 2022, which is used in varied applications, such as Epoxy Resin, Water Treatment Chemicals, Textiles, Pharmaceuticals, Paper Reinforcement, Synthetic Glycerine, etc. It commissioned CPVC Resinmanufacturing facility with a capacity of 30,000 TPA capacity on 18th July, 2022.In April 2024, the Company commissioned an additional 45,000 TPA capacity of CPVC Resin Plant at its Dahej facility in Gujarat. As a result of this expansion, Companys total CPVC resin capacity reached 75,000 TPA. The Chlorinated Polyvinyl Chloride (CPVC) compound announced the expansion with a capacity of 35,000 TPA with an additional Capex of Rs. 25 Crore in 2024.
Read More

Epigral FAQs

Epigral share price is ₹1738.1 in NSE and ₹1743.65 in BSE as on 20/2/2025 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

Epigral share price in the past 1-year return was 42.24. The Epigral share hit a 1-year low of Rs. 950.25 and a 1-year high of Rs. 2406.75.

The market cap of Epigral is Rs. 7498.4 Cr. as of 20/2/2025 12:00:00 AM.

The PE ratios of Epigral is 21.7 as of 20/2/2025 12:00:00 AM.

The PB ratios of Epigral is 4.34 as of 20/2/2025 12:00:00 AM

The Mutual Fund Shareholding in Epigral was 4.15% at the end of 20/2/2025 12:00:00 AM.

You can easily buy Epigral shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -